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DegradationHDL removes excess cholesterol from peripheral tissues and delivers it to the liver and steroidogenic tissues via
selective lipid uptakewithout catabolism of the HDL particle itself. In addition, endocytosis of HDL holo-particles
has been debated for nearly 40 years. However, neither the connection between HDL endocytosis and selective
lipid uptake, nor the physiological relevance of HDL uptake has been delineated clearly. This review will focus
on HDL endocytosis and resecretion and its relation to cholesterol transfer. Wewill discuss the role of HDL endo-
cytosis in maintaining cholesterol homeostasis in tissues and cell types involved in atherosclerosis, focusing on
liver, macrophages and endothelium. We will critically summarize the current knowledge on the receptors me-
diating HDL endocytosis including SR-BI, F1-ATPase and CD36 and on intracellular HDL transport routes. Depen-
dent on the tissue, HDL is either resecreted (retro-endocytosis) or degraded after endocytosis. Finally, ﬁndings on
HDL transcytosis across the endothelial barrier will be summarized. We suggest that HDL endocytosis and
resecretion is a rather redundant pathway under physiologic conditions. In case of disturbed lipid metabolism,
however, HDL retro-endocytosis represents an alternative pathway that enables tissues to maintain cellular cho-
lesterol homeostasis.
© 2013 The Authors. Published by Elsevier B.V. Open access under CC BY license.1. Introduction
High-density lipoprotein (HDL) exertsmultiple actions onmetabolic
homeostasis and thereby beneﬁcially impacts atherosclerosis, thrombo-
sis, inﬂammation, and glucose homeostasis. Importantly, HDL removes
excess cholesterol from peripheral tissues and cells. These cells include
macrophage foam cells, which are directly involved in atherosclerotic
plaque formation. HDL then transports this cholesterol to the liver for
disposal into the bile. This process of peripheral cholesterol efﬂux to
HDL and delivery to the liver is termed reverse cholesterol transport
(RCT) and is important for the anti-atherogenic properties of HDL.
Thus, high plasma HDL cholesterol levels are generally associated with
reduced risk for cardiovascular diseases [1,2].
Recent studies suggest that HDL is not a mere transport vehicle for
lipids, but is also a carrier of non-lipid cargo such as microRNAs [3].
Further, HDL can inﬂuence cellular signaling by binding to its cell
surface receptors. Hence, the complexity of HDL metabolism is still
incompletely understood, which also holds true for our knowledge on
the transfer of lipids between HDL and target cells. This is in contrast
to our extensive knowledge on the metabolism of low-densityry, Center for Pathobiochemistry
rasse 10, 1090 Vienna, Austria.
Stangl).
V. Open access under CC BY license.lipoprotein (LDL): LDL bound to the LDL receptor (LDL-R) is internalized
via clathrin-coated pits, which fuse with early sorting endosomes. After
dissociation from its receptor, themajority of LDL particles are delivered
to late endosomal compartments for hydrolysis of lipids and protein
degradation [4]. Free cholesterol can then exit late endosomes towards
the endoplasmic reticulum or the plasma membrane. HDL metabolism,
however, is more complex with regard to the cholesterol transport
routes and HDL binds to a variety of cells with varying degrees of spec-
iﬁcity. Accordingly, a number of proteins and receptors have been
described to bind HDL. After receptor binding, HDL transfers lipids to
cells predominantly by selective lipid uptake without catabolism of
the particle [5]. In addition, an alternative pathway comprising endocy-
tosis of whole HDL particles followed by resecretionwas observedmore
than 40 years ago. However, neither the connection between HDL en-
docytosis and selective lipid uptake, nor the physiological relevance of
HDL uptake is fully clariﬁed.
In this review, we will summarize receptors and mechanisms for
HDL endocytosis and resecretion focusing on liver, endothelial cells
and macrophages as central tissues in atherosclerosis development.
2. HDL endocytosis and resecretion
Even though HDL endocytosis was described in themid-seventies of
the last century [6], the relevance of HDL endocytosis for HDL metabo-
lism is still under debate and awaits its complete elucidation. Detailed
analysis of HDL endocytosis was ﬁrst described by Bierman, Stein and
Stein in rat aortic smooth muscle cells. The authors suggested that
HDL catabolism is low. Instead, they reported regurgitation of non-
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resecretion was described in macrophages by two independent studies
of Alamet al. and Schmitz et al. [8,9]. In 1990DeLamatre and co-workers
demonstrated retro-endocytosis of iodinated HDL particles in a rat liver
cell line [10]. However, the receptors involved in HDL binding were not
identiﬁed at this time.
It was not until 1996 that scavenger receptor class B, type I (SR-BI)
was cloned and characterized as an HDL receptor by the group of
Krieger [11,12]. Its human ortholog CLA-1 was described by Calvo and
Vega [13]. The main function of SR-BI is selective cholesteryl ester
uptake of HDL derived lipids by the liver and steroidogenic tissues
[14]. Indeed, SR-BI plays a crucial role in cholesterol homeostasis and
reverse cholesterol transport: Hepatic SR-BI over-expression increases
clearance of plasma cholesterol inmice [15–17] and reduces atheroscle-
rosis [18,19]. In contrast, loss of hepatic SR-BI results in elevated plasma
cholesterol levels leading to atherosclerosis [20]. In humans, a low
abundance mutation in SR-BI leads to increased plasma cholesterol
and impaired steroid hormone synthesis, further underlining the im-
portance of this receptor in lipid metabolism [21].
The transport of lipids from HDL to SR-BI is generally thought
to occur via selective cholesteryl ester uptake, where only the lipid
load of HDL is transferred without concomitant catabolism of the HDL
particle itself [5,22–24]. In addition, SR-BI is a bonaﬁde endocytic recep-
tor as it mediates the internalization of lipopolysaccharides and facili-
tates hepatitis C virus entry [25–27]. Therefore, it is well conceivable
that SR-BI also mediates HDL endocytosis. This connection was ﬁrst
described by the group of Tall: Their experiments in polarized hepato-
cytes and kidney cells showed that SR-BI mediates HDL transport to
the endosomal recycling compartment and apical membrane regions
[28]. Studies in our lab showed concomitant endocytosis of SR-BI and
HDL which was followed by particle resecretion. HDL resecretion
could be linked to cholesterol efﬂux, since resecreted HDL particles
were enriched in cellular cholesterol [29].
Endocytosis and resecretion is not limited to HDL, but instead occurs
with almost all lipoprotein classes: Similar to HDL endocytosis and
resecretion, uptake and resecretion was described for LDL as well as
Lp(a). It is estimated that approximately 20% of endocytosed LDLTable 1
HDL endocytosis in tissue culture.
Cell line Tissue Species
HepG2 Liver Human
HepG2 Liver Human
HUH-7 Liver Human
Primary hepatocytes Liver Mouse
Primary hepatocytes Liver Mouse
Hepa1-6 Liver Mouse
Non-parenchymal liver cells Liver Mouse
FU5AH Liver Rat
Aortic smooth muscle cells Endothelium Rat
Aortic endothelial cells Endothelium Rat
Aortic endothelial cells Endothelium Bovine
HUVEC Endothelium Human
HCAEC Endothelium Human
EPCs Endothelium Human
Peritoneal macrophages Macrophage Mouse
Monocyte-derived macrophages Macrophage Human
THP-1 monocyte/macrophage Macrophage Human
Madin–Darby cells Kidney Canine
HEK293 Kidney Human
Y1BS1 Adrenals Human
Caco-2 Intestine Human
3T3-L1 adipocytes Adipocytes Human
Trophoblasts Placenta Human
BeWO Placenta Human
Prim. capillary endothelial cells Brain Porcine
CHO Ovaries Hamster
CHO7 Ovaries Hamster
COS-7 Fibroblast Monkey
⁎ Röhrl, Fruhwürth, Srisen, Winter, Neumüller and Stangl, unpublished data.escapes lysosomal degradation [30–32]. Additionally, recycling of apoE
is well described [for review: [33]]. ApoE derived from LDL and
triglyceride-rich particles are resistant to degradation and are
resecreted. A functional role for apoE recycling is implicated in the gen-
eration of apoE-rich HDL particles as well as cholesterol efﬂux [34–36].
By now, HDL endocytosis has been shown to occur in cell lines orig-
inating from various tissues (summarized in Table 1). In addition, HDL
endocytosis has been observed in a variety of species including humans,
rodents and even insects and crustaceans [37]. This suggests that HDL
endocytosis is a virtually ubiquitous process. This excludes erythrocytes,
where cholesterol exchange with lipoproteins is considered a passive
process without participation of lipoprotein receptors [38,39].
3. Intracellular HDL trafﬁcking and lipid exchange
While LDL endocytosis is known to occur via clathrin-coated pits [40],
it is under debate if HDL endocytosis is a clathrin-dependent or indepen-
dent process. Inhibition of clathrin-mediated endocytosis inhibited LDL
internalization, but not HDL uptake suggesting clathrin-independent
mechanisms in hepatocytes and SR-BI over-expressing CHO cells [28].
Caveolae are specialized bulb-shaped surface pits enriched in cholesterol
containing caveolin and cavin proteins and are implicated in a variety of
physiological processes including cell signaling and endocytosis. Interest-
ingly, caveolin deﬁciency severely affects lipid homeostasis [41]. SR-BI
was reported to preferentially localize to caveolae and not clathrin-
coated pits in CHO cells over-expressing SR-BI [42]. In contrast, SR-BI is
localized in rafts devoid of caveolin-1 in HepG2 cells [43]. In line with
this observation, HDL is efﬁciently endocytosed via clathrin-coated pits
in HepG2 cells, a cell line devoid of plasma membrane caveolae [44,45].
HDL endocytosis is also clathrin-mediated in Caco-2 cells [46]. Indeed,
the caveolar density remarkably differs in different tissues. Caveolae are
merely detectable in the kidney, whereas they make up to 50% of the
plasma membrane surface in endothelial cells and adipocytes [41]. As
HDL endocytosis seems to be a ubiquitous process, we suggest that
caveolae are no pre-requisite for HDL endocytosis, although the presence
of caveolae might account for a favorable environment to enhance HDL
endocytosis.Ref. Remark
[44,45,71,119,120]
[49,50] Polarized HepG2 cells
⁎
[28] Polarized murine hepatocytes
[55,77]
⁎
[79]
[10]
[6] 1st report of HDL retro-endocytosis
[121]
[93,94]
⁎
⁎
⁎ Endothelial progenitor cells
[8]
[9]
[29]
[28] Polarized epithelial cells
⁎
[29]
[46]
⁎
[60]
[61]
[122] In-vitro model for blood–brain-barrier
[29,52,53,56]
[61] Degrade HDL efﬁciently
[48]
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HDL endocytosis using different methodologies: Using ultrasensitive
ﬂuorescence microcopy in SR-BI over-expressing cells we found that
HDL is endocytosed in clusters of approximately 10particles. HDL clusters
are rapidly transported towards the Golgi-apparatus (v = 0.52 μm/s), a
process requiring functional microtubules [47]. By means of combined
light and electron microscopy, we further showed a central role of
multivesicular bodies – intermediate organelles between early and
late endosomes – in HDL endocytosis in HepG2 cells. HDL accumulated
in multivesicular bodies rather slowly with a peak labeling after three
hours. Further studies suggest that HDL taken up by HepG2 and COS-7
cells is transported to two intracellular pools: A rapid-turnover
retroendocytotic pool (half-life: 3.8 min) and a slow-turnover pool
that is eventually further transported to lysosomes for degradation
[48]. These results are in close agreement with studies by WüstnerFig. 1. Putative contributions of HDL endocytosis and resecretion to RCT. ApoA-I is secreted by
exert athero-protective effects, apoA-I and HDL have to be transported tomacrophage foam cell
cells, whereas SR-BI, ABCG1 and ecto-F1-ATPase facilitate HDL transport. Excessmacrophage fre
endocytosis was shown to mediate cholesterol efﬂux. ABCG1 mainly seems to have a role in in
lymphatics and the vasa vasorum and is transported back to the liver. Here, SR-BI transfers cho
HDL binding site under the control of ecto-F1-ATPase and P2Y13 are discussed to mediat
the endosomal recycling compartment (ERC) and resecreted or transported to multivesicular
endocytosis, HDL exchanges cholesterol with hepatocytes. Cholesterol is then either used for th
sion to bile-acids. Abbreviations: FC (free cholesterol); CE (esteriﬁed cholesterol); apoA-I (apol
ABCA1 (ATP-binding cassette transporter A1); ABCG1 (ATP-binding cassette transporter G1); Cand colleagues, who likewise described a rapid turnover HDL recycling
pool (half-life: 6.9 min) in polarized hepatocytes which likely repre-
sents the endosomal recycling compartment [49,50]. HDL transport to
the ERC is consistent with ﬁndings by Silver et al. [28]. In addition to
this rapid-turnover ERC pool, we propose that multivesicular bodies
represent the slow-turnover pool for HDL endocytosis (Fig. 1) [44].
Although the intracellular trafﬁcking during HDL endocytosis has
been characterized in many aspects, it is still unclear, if endocytosis is
deﬁnitely necessary for selective lipid uptake. Several lines of evidence
suggest that HDL endocytosis is not required for selective uptake:
Liposomes containing puriﬁed SR-BI are sufﬁcient for selective CE uptake
[51]. Moreover, blocking of HDL endocytosis by different experimental
approaches does not interfere with selective uptake [52,53]. Further,
HDL is not endocytosed by luteinized ovaries which require high
amounts of cholesterol for steroid hormone synthesis [54]. In contrast,the liver and intestine (not shown here) and acquires phospholipids and cholesterol. To
s through endothelial cells. ABCA1 is necessary for apoA-I transcytosis through endothelial
e cholesterol is transported to apoA-I by ABCA1 or to HDL by SR-BI. In addition, HDL retro-
tracellular cholesterol trafﬁcking. Cholesterol enriched HDL then leaves the plaque via the
lesterol to hepatocytes by selective lipid uptake. In addition, SR-BI, CD36 and a low afﬁnity
e HDL holo-particle uptake. After endocytosis, HDL is either rapidly recycled through
bodies (MVBs). HDL degradation in lysosomes is limited and occurs rather slowly. During
e formation of new lipoproteins or secreted into the bile directly or indirectly after conver-
ipoprotein A-I); HDL (high-density lipoprotein); SR-BI (scavenger receptor class B, type I);
D36 (cluster of differentiation 36).
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lesterol exchange between HDL and hepatocytes [28,55]. Interestingly,
SR-BII, a splicing variant of SR-BI, was described tomediate endocytosis
of HDL. SR-BII over-expressionwasmore efﬁcient in enhancingHDL up-
take, whereas over-expression of SR-BI wasmore efﬁcient in increasing
selective uptake [56]. This again suggests that selective lipid uptake is
distinct from HDL endocytosis. However, differences between murine
and human SR-BI have been reported: Selective uptake mediated by
expression of CLA-1, the human analog of SR-BI, relies on endocytosis,
whereas selective uptake mediated by murine SR-BI does not [57].
It is thus unclear if HDL endocytosis is essentially required for selec-
tive uptake. However, it is clear that cholesterol exchange occurs during
endocytosis, as several reports suggest modiﬁcation of the HDL particle
after endocytosis: In SR-BI overexpressing cells HDL size ismore hetero-
geneous after resecretion, indicating HDL particle modiﬁcation during
retro-endocytosis [29]. In hepatocytes, resecreted HDL was depleted
in free and esteriﬁed cholesterol which suggests selective lipid uptake
during endocytosis [55]. In contrast, HDL resecretion from cholesterol-
laden macrophages results in secretion of enlarged, cholesterol enriched
HDL [9]. Thus, the cellular cholesterol status might determine if HDL is
cholesterol loaded or depleted during retro-endocytosis.
4. HDL catabolism
While the majority of LDL is catabolized and degraded in lysosomes,
degradation of HDL is generally hard to quantify. In human ﬁbroblasts,
degradation of HDL less than 5% compared to LDL [58] and measurable
HDL degradation is limited to certain cell types. Among these, placenta
trophoblast cells are an interesting example displaying considerable
HDL degradation. Trophoblasts represent the contact zone between
maternal and fetal tissue and their cholesterol handling is especially in-
teresting as the growing embryo most likely depends on the supply of
maternal cholesterol, primarily in the ﬁrst trimester [59]. In ﬁrst trimes-
ter trophoblasts, both HDL degradation and selective uptake from HDL
are high. In term trophoblasts, HDL degradation and selective uptake
are decreased, but still elevated compared to other tissues [60]. Tropho-
blasts are thus capable of dismantling large amounts of HDL, probably to
meet the high cholesterol requirements of the growing embryo. Our in-
vestigations provide evidence for a similar HDL degrading mechanism
in a subclone of CHO7 cells, whichwas adapted to grow under low cho-
lesterol conditions. We described that HDL degradation in both CHO7
and placenta BeWo cells was only partially blocked by chloroquine,
indicating a mechanism distinct from lysosomal degradation, which is
typical for LDL catabolism [61]. Instead, HDL degradation involved
lipases and proteoglycans and probably did not occur intracellularly.
Indeed, a role in HDL catabolism has been attributed to lipases, as both
endothelial lipase and hepatic lipase contribute to HDL remodeling,
which alters the clearance from the circulation by liver and kidney
[62,63].
The liver as a central organ in lipoprotein metabolism does not only
mediate selective CE uptake from HDL, but also HDL endocytosis and
degradation. HDL degradation in hepatocytes seems to be regulated
by leptin and is impaired in ob/ob mice [55]. Hepatic HDL catabolism
is not mediated by SR-BI, as SR-BI-deﬁcient mice show no defect in
HDL catabolism [64,65]. Further, SR-BI-mediated retro-endocytosis in
murine hepatocytes was independent of HDL degradation [28], which
appears to be mediated by a different receptor that remains to be iden-
tiﬁed. The β-chain of ATP synthase (ecto-F1-ATPase; see below), is a
possible candidate mechanism facilitating HDL degradation. The inde-
pendence of HDL degradation of SR-BI makes inhibition of HDL degra-
dation a putative therapeutic strategy for raising HDL levels without
concomitant inhibition of cholesterol clearance from plasma by selec-
tive uptake.
In contrast to the liver, the kidney is generally not regarded as a
central organ in lipoprotein metabolism, because lipoproteins are too
large to pass the glomerular ﬁltration barrier. However, an importantrole is attributed to the kidney in apoA-I catabolism. The role of the
kidney in lipid metabolism as well as the function of the HDL receptors
cubilin and megalin are excellently reviewed elsewhere [66].
Taken together, HDL degradation occurs in metabolically highly
active tissues and in cases, where extracellular cholesterol is limited. It
would be interesting to study HDL degradation in malignant tumors,
as they might rely on high amounts of exogenous cholesterol for prolif-
eration. Indeed, SR-BI expression correlates with the degree of malig-
nancy in melanoma cells (Mikula, Röhrl and Stangl, unpublished
data), suggesting an increased demand for cholesterol in malignant
metastatic tumors.
5. HDL endocytosis in tissues relevant to atherosclerosis
5.1. Liver
The liver is a complex organ composed of various cell types of paren-
chymal (hepatocytes) and non-parenchymal (Kupffer cells, endothelial
cells, stellate cells) origin. Besides nascentHDL formation, the liver plays
a major role in the clearance of HDL derived cholesterol. After injection
of radiolabeled HDL, 22% of liver associated HDL was associated with
Kupffer and endothelial cells, suggesting the importance of these cell
types for HDL metabolism [67]. In hepatocytes, HDL-cholesterol can be
secreted into the bile, converted to bile acids, or secreted via newly syn-
thesized lipoproteins. It has been suggested that HDL and not LDL is the
primary source of bile-cholesterol in humans [68]. Consistent with the
important role of HDL in reverse cholesterol transport – i.e. the trans-
port of macrophage cholesterol to the feces via biliary excretion –
hepatic SR-BI over-expression increases macrophage reverse cholester-
ol transport [69]. SR-BI is expressed at both the basolateral (sinusoidal)
and the apical (bile-canalicular)membrane inmurine liver [15]. InWIF-
B cells, a model for polarized hepatocytes, SR-BI distribution between
the basolateral and apical membrane is regulated by the cellular choles-
terol status [70]. This polarized distribution is consistent with SR-BI
being a receptor for basolateral to apical cholesterol transport into the
bile. Whether SR-BI mediates biliary cholesterol secretion via holo-
particle uptake, however, is under debate. It was shown that SR-BI
mediates HDL endocytosis in polarized HepG2 cells. However, free
cholesterol rapidly dissociated from HDL and was transported to the
apical bile-canalicular membrane independent of HDL [50]. In contrast,
Bodipy-CE as a marker for esteriﬁed cholesterol was transported to the
bile-canalicularmembrane concomitantlywith HDL in polarized prima-
ry hepatocytes [28]. These conﬂicting results can be rationalized by dif-
ferent cellular trafﬁcking of free and esteriﬁed cholesterol [71]. Probably
intracellular HDL trafﬁcking is not important for amphiphilic free
cholesterol transport to bile-canaliculi, because free cholesterol rapidly
dissociates from the HDL particle and is efﬁciently transported by
non-vesicular mechanisms.
In contrast to these in-vitro studies in SR-BI over-expressing cells,
SR-BI knockout mice display unchanged holo-HDL uptake into the
liver, whereas selective lipid uptake is considerably diminished [72].
This argues against a role for SR-BI in hepatic HDL uptake. In line with
a minor role of SR-BI in hepatic HDL endocytosis is the extensive work
of Laurent Martinez on an SR-BI-independent mechanism of HDL inter-
nalization in hepatic cells in-vitro and in-vivo: Thismechanism requires
apoA-I binding to a high afﬁnity receptor identiﬁed as the cell surface
expressed β-chain of ATP synthase (ecto-F1-ATPase), which is normally
localized in the inner mitochondrial membrane [73]. ApoA-I binding to
ecto-F1-ATPase induces the hydrolysis of ATP to ADPwhich in turn acti-
vates HDL endocytosis by a low afﬁnity receptor that remains to be
identiﬁed (Fig. 1). This endocytosis is clathrin-mediated and depen-
dents on the activation of the purinergic receptor P2Y13 by the generat-
ed ADP [74]. Indeed, HDL endocytosiswas found to be dependent on the
extracellular ADP concentration and on enzymes modulating these
levels [75]. Further characterization of this pathway showed its depen-
dence on the GTPase signaling as well as cytoskeletal reorganization
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ﬁrmed in-vivo: P2Y13-deﬁcient mice exhibited decreased hepatic HDL
and cholesterol uptake as well as decreased bilary cholesterol secretion
and total macrophage-to-feces RCT [77]. Thus, P2Y13 is putative thera-
peutic target as a regulator of hepatic HDL endocytosis [78]. Besides
the liver, ecto-F1-ATPase plays a role in HDL transcytosis in endothelial
cells (see below).
Another receptor for hepatic holo-HDL particle uptake is scavenger
receptor cluster of differentiation 36 (CD36), as recently reported by
Rinninger's group [79]. CD36 shows a high degree of sequence homology
in its extracellular domain compared to SR-BI. CD36 is a high afﬁnity HDL
receptor; in addition, CD36 has a broad spectrum of ligand as it is know
from SR-BI. Given the high homology it is not surprising that CD36 also
mediates selective lipid uptake from HDL, although less efﬁciently than
SR-BI [80,81]. Moreover, CD36 promotes HDL endocytosis, especially in
the liver [79]. HDL uptake by CD36 was shown in both hepatocytes and
non-parenchymal liver cells. Interestingly, non-parenchymal liver cells
showedhigherHDLholo-particle uptake thanhepatocyteswhennormal-
ized to cell protein.
5.2. Macrophages
Macrophages play a crucial role in the pathogenesis of atherosclero-
sis. Endothelial inﬂammation leads to recruitment and invasion of
monocytes/macrophages which excessively internalize modiﬁed lipo-
proteins. Excess cholesterol uptake triggersmacrophage foam cell forma-
tion and pronounced inﬂammatory responses. Subsequent accumulation
of cells, lipid andmatrix leads to necrotic breakdown of some lesions and
thrombosis [82]. Nascent andmatureHDLparticles can accept cholesterol
from macrophages in atherosclerotic lesions and thereby counteract
foam cell formation (Fig. 1). Major cholesterol efﬂux pathways include
aqueous diffusion as well as ABCA1, ABCG1 and SR-BI-dependent pro-
cesses [83]. If HDL endocytosis and resecretion also contribute to macro-
phage cholesterol homeostasis, remains to be clariﬁed (this question is
also addressed by a review article by Cavelier and colleagues [84]).
HDL uptake and resecretion in cholesterol-laden mouse peritoneal
macrophages was the topic of one of the ﬁrst reports of HDL retro-
endocytosis [8]. Subsequent to receptor-mediated binding, HDL was
internalized and transported into endosomes as demonstrated using
gold-labeled HDL. HDL containing endosomes did not fuse with lyso-
somes and consistently, degradation was limited. Instead, HDL contain-
ing compartments were found to interact with lipid droplets, which
might lead to direct exchange of cholesterol from lipid droplets to
HDL. In this study, HDL2 showed a higher uptake thanHDL3 [8]. In a sub-
sequent report, Alam and colleagues conﬁrmed enhanced internaliza-
tion of apoE-free HDL in human monocyte-derived macrophages upon
cholesterol loading. They found internalized HDL to be resecreted as
larger ApoE-containing HDL2-like particles and hypothesized that HDL
resecretion facilitates removal of excess cholesterol from cells [9].
More recently, we have also described HDL endocytosis and resecretion
in THP-1 monocytes/macrophages [29]. In contrast, two studies report
that HDL is not taken up in mouse peritoneal or RAW macrophages
[85,86]. Although it is still unclear, if HDL retro-endocytosis contributes
to cholesterol efﬂux, retro-endocytosis of free apoA-I might be impor-
tant for cholesterol efﬂux [86,87]. Candidate receptors for HDL endocy-
tosis in macrophages are the scavenger receptors SR-BI, CD36 and SR-A,
which bind a broad spectrum of ligands as well as ABCG1, although the
presence of this receptor at the plasmamembrane has been questioned
recently [88].
5.3. Endothelium
Interactions of lipoproteins with the vascular endothelium play a
critical role in lipid homeostasis and atherosclerosis: First, endothelial
cells mediate lipolysis of triglyceride-rich lipoproteins. Second, vascular
tone and endothelial integrity can be regulated by lipoproteins [forreview: [89]]. Third, lipoproteins as well as monocyte/macrophages
have to pass the endothelium to interact with atherosclerotic lesions.
HDL can pass the endothelial barrier more easily than VLDL and LDL,
presumably due to its smaller size [90]. HDL is considered to be actively
transported through endothelial cells by transcytosis, which involves
apical endocytosis, intracellular trafﬁcking and basolateral exocytosis.
In arteries, HDL transcytosis only occurs from the plasma towards the
intima and not in the reverse direction. Instead, HDL leaves the intima
via the vasa vasorum and the lymphatics [91]. Recently, the important
role of the lymphatics in removal of HDL from plaques and RCT was
directly demonstrated [92].
Extensive work in the group of von Eckardstein revealed that both
SR-BI and ABCG1 mediate HDL transcytosis in polarized bovine aortic
endothelial cells (Fig. 1) [93]. This group showed a role for ecto-F1-
ATPase in regulating HDL transcytosis [94]. If ecto-F1-ATPase is causally
involved in SR-BI andABCG1mediatedHDL endocytosis, is not yet prov-
en. Instead, HDL transcytosis through endothelial cells might involve
several redundant receptors since co-silencing of SR-BI and ABCG1
reduced HDL transcytosis by 30% only [93]. This strongly suggests in-
volvement of other factors inHDL transcytosis. Given the high abundance
of caveolae in endothelial cells, their contribution to HDL transcytosis
seems plausible. However, a role of caveolae has so far only been
shown in the transendothelial transport of LDL [95]. Interestingly, over-
expression of endothelial caveolin-1 leads to enhanced atherosclerosis
[96] which could be interpreted as a result of increased LDL transcytosis
resulting in enhanced foam cell formation.
Glycosylphosphatidylinositol-anchored high density lipoprotein-
binding protein 1 (GPIHBP1) was initially described as an HDL receptor
and is highly expressed in endothelial cells in-vivo [97]. However,
GPIHBP1 knockout mice have major defects in the lipolysis of triglycer-
ide lipoproteins and not in HDLmetabolism [98].Moreover, GPIHBP-1 is
not expressed in large artery endothelial cells, even though the large
arteries display HDL transcytosis. This suggests that GPIHBP-1 does
not mediate HDL transcytosis in vascular endothelial cells.
While vascular endothelial cells are studied extensively in terms of
HDL transcytosis, HDL transport through lymphatic endothelial cells
has been largely neglected previously. A recent report showed that lym-
phatic endothelial cells express ABCA1 and SR-BI, but not ABCG1 [92].
This study revealed that cholesterol removal from atherosclerotic
plaques requires active transport of HDL through lymphatic endothelial
cells, which is mediated by SR-BI.
5.4. Adipose tissue
Adipose tissue is the major storage site for triglycerides and thus
plays a central role in energy metabolism. In addition, it is the largest
reservoir for free cholesterol and a direct modulator of cholesterol
metabolism: Adipocyte ABCA1 mediates cholesterol efﬂux in-vitro
[99] and consistently, adipose tissue signiﬁcantly contributes to HDL
biogenesis in-vivo [100]. In addition, adipose tissue is involved in the
clearance of HDL derived cholesterol from the circulation, which is me-
diated by SR-BI [101,102]. HDL endocytosiswas described in adipocytes,
but its signiﬁcance is unclear. Like in other cell types, selective CEuptake
exceeds holo-particle uptake in adipocytes [103,104]. Adipocytes
express ecto-F1-ATPase and its expression increases during adipocyte
differentiation [105]. Adipocyte ecto-F1-ATPase mediates endocytosis
and resecretion of free apoA-I. However, this apoA-I recycling is not
accompanied by cholesterol efﬂux and its physiological function is
unknown yet [106]. If ecto-F1-ATPase is also involved in the regulation
of HDL endocytosis remains to be investigated.
5.5. Platelets
Platelets are directly involved in atherosclerotic plaque formation
and thrombosis. As HDL cholesterol levels are inversely related to
thrombosis risk, the interaction of HDLwith platelets is under extensive
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mice display defects in platelet structure and function [108]. However,
this effect was largely attributed to dyslipidemia in these mice rather
than to the absence of the receptor in platelets per se [109,110]. Evi-
dence for a direct role of platelet SR-BI was provided recently in a
study which identiﬁed HDL associated phospholipids as important
modulators of the anti-thrombotic action of HDL [111]. Another study
suggests that the reduction of platelet membrane cholesterol by efﬂux
to reconstituted HDL can be utilized as a therapeutic approach to inhibit
platelet activation [112]. However, the effects of HDL on platelet activa-
tion were generally attributed to alterations in cell signaling and a role
for HDL endocytosis has not been investigated yet.
6. Conclusions and perspectives
Despite the fact that HDL endocytosis has been known for more
than 40 years, its physiological relevance is still under debate. HDL en-
docytosis does not seem to be a major contributor to maintain cellular
cholesterol homeostasis. It is generally accepted that selective lipid up-
take exceeds HDL protein uptake and is highly efﬁcient [5]. However,
various pieces of evidence point towards a redundant function of HDL
holo-particle uptake in cases where normal mechanisms to maintain
cellular cholesterol homeostasis are disturbed.
In SR-BI knockout mice, HDL endocytosis in adrenals is enhanced,
suggesting a compensation for reduced selective lipid uptake [72].
Further evidences for HDL endocytosis as a redundant pathway come
from our ﬁndings in cells derived from patients with Niemann–Pick
disease, where the LDL-receptor pathway and late endosomal choles-
terol trafﬁcking are impaired. In ﬁbroblasts from these patients, HDL
retro-endocytosis is still functional in maintaining cellular cholesterol
homeostasis [113]. Similarly, HDL and LDL resecretion mediates choles-
terol efﬂux in ﬁbroblasts from patients with Tangier disease, where
ABCA1 function and cholesterol efﬂux to apoA-I are defective (Neuhofer
and Stangl, unpublished data).
In case of low cholesterol availability and high cholesterol demand,
cells seem to adapt toHDL endocytosis and degradation to supply them-
selves with cholesterol [61]. Is HDL endocytosis therefore a redundant
pathway that only becomes important in pathologic conditions? Impor-
tantly, redundancy is not only found in case of HDL pathways, but may
also exist between lipoprotein classes, where one lipoprotein species
steps in for another: In cells lacking a functional LDL-receptor, SR-BI
mediates both selective and holo-particle uptake from LDL [29,114].
Another hypothesis for an essential function of holo-particle uptake is
cholesterol delivery to distinct cellular pools. In hepatocytes, for instance,
there is evidence for distinct functional cholesterol pools, one for bile-acid
synthesis and one for direct cholesterol secretion into the bile [115]. One
can speculate that HDL endocytosis transports cholesterol to an intracel-
lular pool that is different from the one supplied by selective uptake.
Taken together, the role of HDL uptake and resecretion in cholesterol
homeostasis is still insufﬁciently deﬁned. However, the function of HDL
as a transport vehicle is not restricted to cholesterol. Instead, HDL cargo
comprises a multitude of lipid species, hormones, proteins and nucleic
acids [3]. For instance, HDL can transport microRNAs to target cells
to modulate gene expression [116]. Moreover, at least 50 distinct
proteins are associated with HDL, many of which are related to anti-
inﬂammatory and anti-oxidative functions [117,118]. It is interesting
to hypothesize that HDL endocytosis has a yet elusive role in transfer
of non-lipid cargo. HDL might acquire proteins and microRNAs during
intracellular trafﬁcking, and endocytosis in target cells might be re-
quired for unloading this non-lipid cargo.
Acknowledgements
The authors are funded by the Austrian Science Fund (FWF):
P22838-B13 (to H.S.) and P25763-B13 (to C.R.). We are grateful to
Witta Monika Strobl for critical discussion.References
[1] P. Barter, A.M. Gotto, J.C. LaRosa, J. Maroni, M. Szarek, S.M. Grundy, J.J. Kastelein, V.
Bittner, J.C. Fruchart, HDL cholesterol, very low levels of LDL cholesterol, and
cardiovascular events, N. Engl. J. Med. 357 (2007) 1301–1310.
[2] B.G. Drew, K.A. Rye, S.J. Duffy, P. Barter, B.A. Kingwell, The emerging role of HDL in
glucose metabolism, Nat. Rev. Endocrinol. 8 (2012) 237–245.
[3] K.C. Vickers, A.T. Remaley, Functional diversity of HDL cargo, J. Lipid Res. (2013),
http://dx.doi.org/10.1194/jlr.R035964.
[4] J.L. Goldstein, M.S. Brown, R.G. Anderson, D.W. Russell, W.J. Schneider, Receptor-
mediated endocytosis: concepts emerging from the LDL receptor system, Annu.
Rev. Cell Biol. 1 (1985) 1–39.
[5] C. Glass, R.C. Pittman, D.B. Weinstein, D. Steinberg, Dissociation of tissue uptake of
cholesterol ester from that of apoprotein A-I of rat plasma high density lipoprotein:
selective delivery of cholesterol ester to liver, adrenal, and gonad, Proc. Natl. Acad.
Sci. U. S. A. 80 (1983) 5435–5439.
[6] E.L. Bierman, O. Stein, Y. Stein, Lipoprotein uptake and metabolism by rat aortic
smooth muscle cells in tissue culture, Circ. Res. 35 (1974) 136–150.
[7] O. Stein, Y. Stein, Comparative uptake of rat and human serum low-density and
high-density lipoproteins by rat aortic smooth muscle cells in culture, Circ. Res.
36 (1975) 436–443.
[8] G. Schmitz, H. Robenek, U. Lohmann, G. Assmann, Interaction of high density
lipoproteinswith cholesteryl ester-ladenmacrophages: biochemical andmorpholog-
ical characterization of cell surface receptor binding, endocytosis and resecretion of
high density lipoproteins by macrophages, EMBO J. 4 (1985) 613–622.
[9] R. Alam, F.M. Yatsu, L. Tsui, S. Alam, Receptor-mediated uptake and ‘retroendocytosis’
of high-density lipoproteins by cholesterol-loaded humanmonocyte-derivedmacro-
phages: possible role in enhancing reverse cholesterol transport, Biochim. Biophys.
Acta 1004 (1989) 292–299.
[10] J.G. DeLamatre, T.G. Sarphie, R.C. Archibold, C.A. Hornick, Metabolism of apoE-free
high density lipoproteins in rat hepatoma cells: evidence for a retroendocytic
pathway, J. Lipid Res. 31 (1990) 191–202.
[11] S. Acton, A. Rigotti, K.T. Landschulz, S. Xu, H.H. Hobbs, M. Krieger, Identiﬁcation of
scavenger receptor SR-BI as a high density lipoprotein receptor, Science 271 (1996)
518–520.
[12] S.L. Acton, P.E. Scherer, H.F. Lodish, M. Krieger, Expression cloning of SR-BI, a
CD36-related class B scavenger receptor, J. Biol. Chem. 269 (1994) 21003–21009.
[13] D. Calvo, M.A. Vega, Identiﬁcation, primary structure, and distribution of CLA-1,
a novel member of the CD36/LIMPII gene family, J. Biol. Chem. 268 (1993)
18929–18935.
[14] S. Azhar, E. Reaven, Scavenger receptor class BI and selective cholesteryl ester
uptake: partners in the regulation of steroidogenesis, Mol. Cell. Endocrinol. 195
(2002) 1–26.
[15] K.F. Kozarsky, M.H. Donahee, A. Rigotti, S.N. Iqbal, E.R. Edelman, M. Krieger,
Overexpression of the HDL receptor SR-BI alters plasma HDL and bile cholesterol
levels, Nature 387 (1997) 414–417.
[16] N. Wang, T. Arai, Y. Ji, F. Rinninger, A.R. Tall, Liver-speciﬁc overexpression of
scavenger receptor BI decreases levels of very low density lipoprotein ApoB, low
density lipoprotein ApoB, and high density lipoprotein in transgenic mice, J. Biol.
Chem. 273 (1998) 32920–32926.
[17] Y. Ueda, L. Royer, E. Gong, J. Zhang, P.N. Cooper, O. Francone, E.M. Rubin, Lower
plasma levels and accelerated clearance of high density lipoprotein (HDL) and
non-HDL cholesterol in scavenger receptor class B type I transgenic mice, J. Biol.
Chem. 274 (1999) 7165–7171.
[18] K.F. Kozarsky, M.H. Donahee, J.M. Glick, M. Krieger, D.J. Rader, Gene transfer and
hepatic overexpression of the HDL receptor SR-BI reduces atherosclerosis in the
cholesterol-fed LDL receptor-deﬁcient mouse, Arterioscler. Thromb. Vasc. Biol. 20
(2000) 721–727.
[19] T. Arai, N. Wang, M. Bezouevski, C. Welch, A.R. Tall, Decreased atherosclerosis
in heterozygous low density lipoprotein receptor-deﬁcient mice expressing the
scavenger receptor BI transgene, J. Biol. Chem. 274 (1999) 2366–2371.
[20] T. Huby, C. Doucet, C. Dachet, B. Ouzilleau, Y. Ueda, V. Afzal, E. Rubin, M.J. Chapman,
P. Lesnik, Knockdown expression and hepatic deﬁciency reveal an atheroprotective
role for SR-BI in liver and peripheral tissues, J. Clin. Invest. 116 (2006) 2767–2776.
[21] M. Vergeer, S.J. Korporaal, R. Franssen, I. Meurs, R. Out, G.K. Hovingh, M. Hoekstra,
J.A. Sierts, G.M. Dallinga-Thie, M.M. Motazacker, A.G. Holleboom, T.J. Van Berkel, J.J.
Kastelein, M. Van Eck, J.A. Kuivenhoven, Genetic variant of the scavenger receptor
BI in humans, N. Engl. J. Med. 364 (2011) 136–145.
[22] T.P. Knecht, R.C. Pittman, A plasma membrane pool of cholesteryl esters that may
mediate the selective uptake of cholesteryl esters from high-density lipoproteins,
Biochim. Biophys. Acta 1002 (1989) 365–375.
[23] R.C. Pittman, T.P. Knecht, M.S. Rosenbaum, C.A. Taylor Jr., A nonendocytotic mecha-
nism for the selective uptake of high density lipoprotein-associated cholesterol esters,
J. Biol. Chem. 262 (1987) 2443–2450.
[24] C. Glass, R.C. Pittman, M. Civen, D. Steinberg, Uptake of high-density lipoprotein-
associated apoprotein A-I and cholesterol esters by 16 tissues of the rat in vivo and
by adrenal cells and hepatocytes in vitro, J. Biol. Chem. 260 (1985) 744–750.
[25] H. Barth, R. Cerino, M. Arcuri, M. Hoffmann, P. Schurmann, M.I. Adah, B. Gissler, X.
Zhao, V. Ghisetti, B. Lavezzo, H.E. Blum, F. vonWeizsacker, A. Vitelli, E. Scarselli, T.F.
Baumert, Scavenger receptor class B type I and hepatitis C virus infection of prima-
ry tupaia hepatocytes, J. Virol. 79 (2005) 5774–5785.
[26] C. Voisset, N. Callens, E. Blanchard, A. Op De Beeck, J. Dubuisson, N. Vu-Dac,
High density lipoproteins facilitate hepatitis C virus entry through the scavenger
receptor class B type I, J. Biol. Chem. 280 (2005) 7793–7799.
[27] T.G. Vishnyakova, A.V. Bocharov, I.N. Baranova, Z. Chen, A.T. Remaley, G. Csako, T.L.
Eggerman, A.P. Patterson, Binding and internalization of lipopolysaccharide by
1632 C. Röhrl, H. Stangl / Biochimica et Biophysica Acta 1831 (2013) 1626–1633Cla-1, a human orthologue of rodent scavenger receptor B1, J. Biol. Chem. 278
(2003) 22771–22780.
[28] D.L. Silver, N. Wang, X. Xiao, A.R. Tall, High density lipoprotein (HDL) particle
uptake mediated by scavenger receptor class B type 1 results in selective sorting
of HDL cholesterol from protein and polarized cholesterol secretion, J. Biol. Chem.
276 (2001) 25287–25293.
[29] T.A. Pagler, S. Rhode, A. Neuhofer, H. Laggner, W. Strobl, C. Hinterndorfer, I. Volf, M.
Pavelka, E.R. Eckhardt, D.R. van der Westhuyzen, G.J. Schutz, H. Stangl,
SR-BI-mediated high density lipoprotein (HDL) endocytosis leads to HDL
resecretion facilitating cholesterol efﬂux, J. Biol. Chem. 281 (2006) 11193–11204.
[30] P. Greenspan, R.W. St Clair, Retroendocytosis of low density lipoprotein. Effect of
lysosomal inhibitors on the release of undegraded 125I-low density lipoprotein
of altered composition from skin ﬁbroblasts in culture, J. Biol. Chem. 259 (1984)
1703–1713.
[31] T.H. Aulinskas, D.R. van der Westhuyzen, E.L. Bierman, W. Gevers, G.A. Coetzee,
Retro-endocytosis of low density lipoprotein by cultured bovine aortic smooth
muscle cells, Biochim. Biophys. Acta 664 (1981) 255–265.
[32] M.L. Snyder, D. Polacek, A.M. Scanu, G.M. Fless, Comparative binding and degrada-
tion of lipoprotein(a) and low density lipoprotein by human monocyte-derived
macrophages, J. Biol. Chem. 267 (1992) 339–346.
[33] J. Heeren, U. Beisiegel, T. Grewal, Apolipoprotein E recycling: implications for
dyslipidemia and atherosclerosis, Arterioscler. Thromb. Vasc. Biol. 26 (2006) 442–448.
[34] A. Laatsch, M. Panteli, M. Sornsakrin, B. Hoffzimmer, T. Grewal, J. Heeren, Low den-
sity lipoprotein receptor-related protein 1 dependent endosomal trapping and
recycling of apolipoprotein E, PLoS One 7 (2012) e29385.
[35] P.C. Rensen, M.C. Jong, L.C. van Vark, H. van der Boom, W.L. Hendriks, T.J. van
Berkel, E.A. Biessen, L.M. Havekes, Apolipoprotein E is resistant to intracellular
degradation in vitro and in vivo. Evidence for retroendocytosis, J. Biol. Chem. 275
(2000) 8564–8571.
[36] A.H. Hasty, M.R. Plummer, K.H. Weisgraber, M.F. Linton, S. Fazio, L.L. Swift, The
recycling of apolipoprotein E inmacrophages: inﬂuence of HDL and apolipoprotein
A-I, J. Lipid Res. 46 (2005) 1433–1439.
[37] B.K. Kang, E. Spaziani, Uptake of high-density lipoprotein by Y-organs of the crab
cancer antennarius: III. Evidence for adsorptive endocytosis and the absence of
lysosomal processing, J. Exp. Zool. 273 (1995) 425–433.
[38] Y. Lange, A.L. Molinaro, T.R. Chauncey, T.L. Steck, On the mechanism of transfer
of cholesterol between human erythrocytes and plasma, J. Biol. Chem. 258 (1983)
6920–6926.
[39] H. Czarnecka, S. Yokoyama, Regulation of cellular cholesterol efﬂux by lecithin:
cholesterol acyltransferase reaction through nonspeciﬁc lipid exchange, J. Biol.
Chem. 271 (1996) 2023–2028.
[40] R.G. Anderson, M.S. Brown, J.L. Goldstein, Role of the coated endocytic vesicle in
the uptake of receptor-bound low density lipoprotein in human ﬁbroblasts, Cell
10 (1977) 351–364.
[41] R.G. Parton, M.A. del Pozo, Caveolae as plasma membrane sensors, protectors and
organizers, Nat. Rev. Mol. Cell Biol. 14 (2013) 98–112.
[42] J. Babitt, B. Trigatti, A. Rigotti, E.J. Smart, R.G. Anderson, S. Xu, M. Krieger, Murine
SR-BI, a high density lipoprotein receptor that mediates selective lipid uptake, is
N-glycosylated and fatty acylated and colocalizeswith plasmamembrane caveolae,
J. Biol. Chem. 272 (1997) 13242–13249.
[43] D. Rhainds, P. Bourgeois, G. Bourret, K. Huard, L. Falstrault, L. Brissette, Localization
and regulation of SR-BI in membrane rafts of HepG2 cells, J. Cell Sci. 117 (2004)
3095–3105.
[44] C. Rohrl, T.A. Pagler, W. Strobl, A. Ellinger, J. Neumuller, M. Pavelka, H. Stangl, C.
Meisslitzer-Ruppitsch, Characterization of endocytic compartments after holo-high
density lipoprotein particle uptake in HepG2 cells, Histochem. Cell Biol. 133 (2010)
261–272.
[45] A. Garcia, R. Barbaras, X. Collet, A. Bogyo, H. Chap, B. Perret, High-density lipopro-
tein 3 receptor-dependent endocytosis pathway in a human hepatoma cell line
(HepG2), Biochemistry 35 (1996) 13064–13071.
[46] A. Klinger, F.M. Reimann, M.H. Klinger, E.F. Stange, Clathrin-mediated endocytosis
of high density lipoprotein3 in human intestinal Caco-2 cells. A post-embedding
immunocytochemical study, Biochim. Biophys. Acta 1345 (1997) 65–70.
[47] S. Rhode, A. Breuer, J. Hesse, M. Sonnleitner, T.A. Pagler, M. Doringer, G.J. Schutz, H.
Stangl, Visualization of the uptake of individual hdl particles in living cells via the
scavenger receptor class B type I, Cell Biochem. Biophys. 41 (2004) 343–356.
[48] B. Sun, E.R. Eckhardt, S. Shetty, D.R. van der Westhuyzen, N.R. Webb, Quantitative
analysis of SR-BI-dependent HDL retroendocytosis in hepatocytes and ﬁbroblasts,
J. Lipid Res. 47 (2006) 1700–1713.
[49] D. Wustner, Mathematical analysis of hepatic high density lipoprotein transport
based on quantitative imaging data, J. Biol. Chem. 280 (2005) 6766–6779.
[50] D. Wustner, M. Mondal, A. Huang, F.R. Maxﬁeld, Different transport routes for high
density lipoprotein and its associated free sterol in polarized hepatic cells, J. Lipid
Res. 45 (2004) 427–437.
[51] B. Liu, M. Krieger, Highly puriﬁed scavenger receptor class B, type I reconstituted
intophosphatidylcholine/cholesterol liposomesmediateshigh afﬁnityhighdensity li-
poprotein binding and selective lipid uptake, J. Biol. Chem. 277 (2002) 34125–34135.
[52] T.J. Nieland, M. Ehrlich, M. Krieger, T. Kirchhausen, Endocytosis is not required for
the selective lipid uptake mediated by murine SR-BI, Biochim. Biophys. Acta 1734
(2005) 44–51.
[53] C.J. Harder, G. Vassiliou, H.M. McBride, R. McPherson, Hepatic SR-BI-mediated
cholesteryl ester selective uptake occurs with unaltered efﬁciency in the absence
of cellular energy, J. Lipid Res. 47 (2006) 492–503.
[54] E. Reaven, Y.D. Chen, M. Spicher, S. Azhar, Morphological evidence that high
density lipoproteins are not internalized by steroid-producing cells during in situ
organ perfusion, J. Clin. Invest. 74 (1984) 1384–1397.[55] D.L. Silver, N. Wang, A.R. Tall, Defective HDL particle uptake in ob/ob hepatocytes
causes decreased recycling, degradation, and selective lipid uptake, J. Clin. Invest.
105 (2000) 151–159.
[56] E.R. Eckhardt, L. Cai, B. Sun, N.R. Webb, D.R. van der Westhuyzen, High density lipo-
protein uptake by scavenger receptor SR-BII, J. Biol. Chem. 279 (2004) 14372–14381.
[57] Y. Zhang, A.M. Ahmed, T.L. Tran, J. Lin, N. McFarlane, D.R. Boreham, S.A. Igdoura, R.
Truant, B.L. Trigatti, The inhibition of endocytosis affects HDL-lipid uptake mediat-
ed by the human scavenger receptor class B type I, Mol. Membr. Biol. 24 (2007)
442–454.
[58] N.E. Miller, D.B. Weinstein, D. Steinberg, Binding, internalization, and degradation
of high density lipoprotein by cultured normal human ﬁbroblasts, J. Lipid Res. 18
(1977) 438–450.
[59] N. Bansal, J.K. Cruickshank, P. McElduff, P.N. Durrington, Cord blood lipoproteins
and prenatal inﬂuences, Curr. Opin. Lipidol. 16 (2005) 400–408.
[60] C. Wadsack, A. Hammer, S. Levak-Frank, G. Desoye, K.F. Kozarsky, B. Hirschmugl,
W. Sattler, E. Malle, Selective cholesteryl ester uptake from high density lipopro-
tein by human ﬁrst trimester and term villous trophoblast cells, Placenta 24
(2003) 131–143.
[61] T.A. Pagler, S. Golsabahi, M. Doringer, S. Rhode, G.J. Schutz, M. Pavelka, C. Wadsack,
M. Gauster, A. Lohninger, H. Laggner, W. Strobl, H. Stangl, A Chinese hamster ovar-
ian cell line imports cholesterol by high density lipoprotein degradation, J. Biol.
Chem. 281 (2006) 38159–38171.
[62] C. Maugeais, U.J. Tietge, U.C. Broedl, D. Marchadier, W. Cain, M.G. McCoy, S.
Lund-Katz, J.M. Glick, D.J. Rader, Dose-dependent acceleration of high-density lipo-
protein catabolism by endothelial lipase, Circulation 108 (2003) 2121–2126.
[63] C. Xiao, T. Watanabe, Y. Zhang, B. Trigatti, L. Szeto, P.W. Connelly, S. Marcovina, T.
Vaisar, J.W. Heinecke, G.F. Lewis, Enhanced cellular uptake of remnant high-density
lipoprotein particles: a mechanism for high-density lipoprotein lowering in insulin
resistance and hypertriglyceridemia, Circ. Res. 103 (2008) 159–166.
[64] A. Rigotti, B.L. Trigatti, M. Penman, H. Rayburn, J. Herz, M. Krieger, A targeted mu-
tation in the murine gene encoding the high density lipoprotein (HDL) receptor
scavenger receptor class B type I reveals its key role in HDL metabolism, Proc.
Natl. Acad. Sci. U. S. A. 94 (1997) 12610–12615.
[65] M.L. Varban, F. Rinninger, N. Wang, V. Fairchild-Huntress, J.H. Dunmore, Q. Fang,
M.L. Gosselin, K.L. Dixon, J.D. Deeds, S.L. Acton, A.R. Tall, D. Huszar, Targeted muta-
tion reveals a central role for SR-BI in hepatic selective uptake of high density lipo-
protein cholesterol, Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 4619–4624.
[66] S.K. Moestrup, L.B. Nielsen, The role of the kidney in lipid metabolism, Curr. Opin.
Lipidol. 16 (2005) 301–306.
[67] D. Schouten, M. Kleinherenbrink-Stins, A. Brouwer, D.L. Knook, T.J. Van Berkel,
Interaction in vivo and in vitro of apolipoprotein E-free high-density lipoprotein
with parenchymal, endothelial and Kupffer cells from rat liver, Biochem. J. 256
(1988) 615–621.
[68] C.C. Schwartz, L.G. Halloran, Z.R. Vlahcevic, D.H. Gregory, L. Swell, Preferential uti-
lization of free cholesterol from high-density lipoproteins for biliary cholesterol se-
cretion in man, Science 200 (1978) 62–64.
[69] Y. Zhang, J.R. Da Silva, M. Reilly, J.T. Billheimer, G.H. Rothblat, D.J. Rader, Hepatic
expression of scavenger receptor class B type I (SR-BI) is a positive regulator of mac-
rophage reverse cholesterol transport in vivo, J. Clin. Invest. 115 (2005) 2870–2874.
[70] C.J. Harder, A. Meng, P. Rippstein, H.M. McBride, R. McPherson, SR-BI undergoes
cholesterol-stimulated transcytosis to the bile canaliculus in polarized WIF-B
cells, J. Biol. Chem. 282 (2007) 1445–1455.
[71] C. Rohrl, C. Meisslitzer-Ruppitsch, R. Bittman, Z. Li, G. Pabst, R. Prassl, W. Strobl, J.
Neumuller, A. Ellinger, M. Pavelka, H. Stangl, Combined light and electron micros-
copy using diaminobenzidine photooxidation to monitor trafﬁcking of lipids de-
rived from lipoprotein particles, Curr. Pharm. Biotechnol. 13 (2012) 331–340.
[72] M. Brundert, A. Ewert, J. Heeren, B. Behrendt, R. Ramakrishnan, H. Greten, M.
Merkel, F. Rinninger, Scavenger receptor class B type I mediates the selective
uptake of high-density lipoprotein-associated cholesteryl ester by the liver in
mice, Arterioscler. Thromb. Vasc. Biol. 25 (2005) 143–148.
[73] L.O. Martinez, S. Jacquet, J.P. Esteve, C. Rolland, E. Cabezon, E. Champagne, T.
Pineau, V. Georgeaud, J.E. Walker, F. Terce, X. Collet, B. Perret, R. Barbaras, Ectopic
beta-chain of ATP synthase is an apolipoprotein A-I receptor in hepatic HDL endo-
cytosis, Nature 421 (2003) 75–79.
[74] S. Jacquet, C. Malaval, L.O. Martinez, K. Sak, C. Rolland, C. Perez, M. Nauze, E.
Champagne, F. Terce, C. Gachet, B. Perret, X. Collet, J.M. Boeynaems, R. Barbaras,
The nucleotide receptor P2Y13 is a key regulator of hepatic high-density lipopro-
tein (HDL) endocytosis, Cell. Mol. Life Sci. 62 (2005) 2508–2515.
[75] A.C. Fabre, P. Vantourout, E. Champagne, F. Terce, C. Rolland, B. Perret, X. Collet, R.
Barbaras, L.O. Martinez, Cell surface adenylate kinase activity regulates the
F(1)-ATPase/P2Y (13)-mediated HDL endocytosis pathway on human hepatocytes,
Cell. Mol. Life Sci. 63 (2006) 2829–2837.
[76] C. Malaval, M. Laffargue, R. Barbaras, C. Rolland, C. Peres, E. Champagne, B. Perret, F.
Terce, X. Collet, L.O. Martinez, RhoA/ROCK I signalling downstream of the P2Y13
ADP-receptor controls HDL endocytosis in human hepatocytes, Cell. Signal. 21
(2009) 120–127.
[77] A.C. Fabre, C. Malaval, A. Ben Addi, C. Verdier, V. Pons, N. Serhan, L. Lichtenstein, G.
Combes, T. Huby, F. Briand, X. Collet, N. Nijstad, U.J. Tietge, B. Robaye, B. Perret, J.M.
Boeynaems, L.O. Martinez, P2Y13 receptor is critical for reverse cholesterol trans-
port, Hepatology (2010), (Baltimore, Md.).
[78] N. Serhan, C. Cabou, C. Verdier, L. Lichtenstein, N. Malet, B. Perret, M. Laffargue, L.O.
Martinez, Chronic pharmacological activation of P2Y13 receptor in mice decreases
HDL-cholesterol level by increasing hepatic HDL uptake and bile acid secretion,
Biochim. Biophys. Acta 1831 (2013) 719–725.
[79] M. Brundert, J. Heeren, M. Merkel, A. Carambia, J. Herkel, P. Groitl, T. Dobner, R.
Ramakrishnan, K.J. Moore, F. Rinninger, Scavenger receptor CD36 mediates uptake
1633C. Röhrl, H. Stangl / Biochimica et Biophysica Acta 1831 (2013) 1626–1633of high density lipoproteins in mice and by cultured cells, J. Lipid Res. 52 (2011)
745–758.
[80] M.A. Connelly, S.M. Klein, S. Azhar, N.A. Abumrad, D.L. Williams, Comparison of
class B scavenger receptors, CD36 and scavenger receptor BI (SR-BI), shows that
both receptors mediate high density lipoprotein-cholesteryl ester selective uptake
but SR-BI exhibits a unique enhancement of cholesteryl ester uptake, J. Biol. Chem.
274 (1999) 41–47.
[81] X. Gu, B. Trigatti, S. Xu, S. Acton, J. Babitt, M. Krieger, The efﬁcient cellular uptake of
high density lipoprotein lipids via scavenger receptor class B type I requires not
only receptor-mediated surface binding but also receptor-speciﬁc lipid transfer
mediated by its extracellular domain, J. Biol. Chem. 273 (1998) 26338–26348.
[82] K.J. Moore, I. Tabas, Macrophages in the pathogenesis of atherosclerosis, Cell 145
(2011) 341–355.
[83] R.S. Rosenson, H.B. Brewer Jr., W.S. Davidson, Z.A. Fayad, V. Fuster, J. Goldstein, M.
Hellerstein, X.C. Jiang, M.C. Phillips, D.J. Rader, A.T. Remaley, G.H. Rothblat, A.R. Tall,
L. Yvan-Charvet, Cholesterol efﬂux and atheroprotection: advancing the concept of
reverse cholesterol transport, Circulation 125 (2012) 1905–1919.
[84] C. Cavelier, I. Lorenzi, L. Rohrer, A. von Eckardstein, Lipid efﬂux by the ATP-binding
cassette transporters ABCA1 and ABCG1, Biochim. Biophys. Acta 1761 (2006)
655–666.
[85] J.F. Oram, C.J. Johnson, T.A. Brown, Interaction of high density lipoprotein with its
receptor on cultured ﬁbroblasts and macrophages. Evidence for reversible binding
at the cell surface without internalization, J. Biol. Chem. 262 (1987) 2405–2410.
[86] I. Lorenzi, A. von Eckardstein, C. Cavelier, S. Radosavljevic, L. Rohrer, Apolipoprotein
A-I but not high-density lipoproteins are internalised by RAWmacrophages: roles
of ATP-binding cassette transporter A1 and scavenger receptor BI, J. Mol. Med. 86
(2008) 171–183.
[87] Y. Takahashi, J.D. Smith, Cholesterol efﬂux to apolipoprotein AI involves endocyto-
sis and resecretion in a calcium-dependent pathway, Proc. Natl. Acad. Sci. U. S. A.
96 (1999) 11358–11363.
[88] E.J. Tarling, P.A. Edwards, ATP binding cassette transporter G1 (ABCG1) is an intra-
cellular sterol transporter, Proc. Natl. Acad. Sci. U. S. A. 108 (2011) 19719–19724.
[89] A. von Eckardstein, L. Rohrer, Transendothelial lipoprotein transport and regula-
tion of endothelial permeability and integrity by lipoproteins, Curr. Opin. Lipidol.
20 (2009) 197–205.
[90] B.G. Nordestgaard, R. Wootton, B. Lewis, Selective retention of VLDL, IDL, and LDL
in the arterial intima of genetically hyperlipidemic rabbits in vivo. Molecular size
as a determinant of fractional loss from the intima-inner media, Arterioscler.
Thromb. Vasc. Biol. 15 (1995) 534–542.
[91] B.G. Nordestgaard, E. Hjelms, S. Stender, K. Kjeldsen, Different efﬂux pathways for
high and low density lipoproteins from porcine aortic intima, Arteriosclerosis 10
(1990) 477–485.
[92] H.Y. Lim, C.H. Thiam, K.P. Yeo, R. Bisoendial, C.S. Hii, K.C. McGrath, K.W. Tan, A.
Heather, J.S. Alexander, V. Angeli, Lymphatic vessels are essential for the removal
of cholesterol from peripheral tissues by SR-BI-mediated transport of HDL, Cell
Metab. 17 (2013) 671–684.
[93] L. Rohrer, P.M. Ohnsorg, M. Lehner, F. Landolt, F. Rinninger, A. von Eckardstein,
High-density lipoprotein transport through aortic endothelial cells involves scav-
enger receptor BI and ATP-binding cassette transporter G1, Circ. Res. 104 (2009)
1142–1150.
[94] C. Cavelier, P.M. Ohnsorg, L. Rohrer, A. von Eckardstein, The beta-chain of cell sur-
face F(0)F(1) ATPase modulates apoA-I and HDL transcytosis through aortic endo-
thelial cells, Arterioscler. Thromb. Vasc. Biol. 32 (2012) 131–139.
[95] P.G. Frank, S. Pavlides, M.W. Cheung, K. Daumer, M.P. Lisanti, Role of caveolin-1 in
the regulation of lipoprotein metabolism, Am. J. Physiol. Cell Physiol. 295 (2008)
C242–C248.
[96] C. Fernandez-Hernando, J. Yu, A. Davalos, J. Prendergast, W.C. Sessa, Endothelial-
speciﬁc overexpression of caveolin-1 accelerates atherosclerosis in apolipoprotein
E-deﬁcient mice, Am. J. Pathol. 177 (2010) 998–1003.
[97] R.X. Ioka, M.J. Kang, S. Kamiyama, D.H. Kim, K. Magoori, A. Kamataki, Y. Ito, Y.A. Takei,
M. Sasaki, T. Suzuki, H. Sasano, S. Takahashi, J. Sakai, T. Fujino, T.T. Yamamoto, Expres-
sion cloning and characterization of a novel glycosylphosphatidylinositol-anchored
high density lipoprotein-binding protein, GPI-HBP1, J. Biol. Chem. 278 (2003)
7344–7349.
[98] A.P. Beigneux, B.S. Davies, P. Gin, M.M. Weinstein, E. Farber, X. Qiao, F. Peale, S.
Bunting, R.L. Walzem, J.S. Wong, W.S. Blaner, Z.M. Ding, K. Melford, N.
Wongsiriroj, X. Shu, F. de Sauvage, R.O. Ryan, L.G. Fong, A. Bensadoun, S.G.
Young, Glycosylphosphatidylinositol-anchored high-density lipoprotein-binding
protein 1 plays a critical role in the lipolytic processing of chylomicrons, Cell
Metab. 5 (2007) 279–291.
[99] A.D. Howard, P.B. Verghese, E.L. Arrese, J.L. Soulages, Characterization of
apoA-I-dependent lipid efﬂux from adipocytes and role of ABCA1, Mol. Cell.
Biochem. 343 (2010) 115–124.
[100] S. Chung, J.K. Sawyer, A.K. Gebre, N. Maeda, J.S. Parks, Adipose tissue ATP binding
cassette transporter A1 contributes to high-density lipoprotein biogenesis
in vivo, Circulation 124 (2011) 1663–1672.[101] S.A. Toh, J.S.Millar, J. Billheimer, I. Fuki, S.U. Naik, C.Macphee,M.Walker, D.J. Rader,
PPARgamma activation redirects macrophage cholesterol from fecal excretion to
adipose tissue uptake in mice via SR-BI, Biochem. Pharmacol. 81 (2011) 934–941.
[102] L. Yvan-Charvet, A. Bobard, P. Bossard, F. Massiera, X. Rousset, G. Ailhaud, M.
Teboul, P. Ferre, G. Dagher, A. Quignard-Boulange, In vivo evidence for a role of
adipose tissue SR-BI in the nutritional and hormonal regulation of adiposity and
cholesterol homeostasis, Arterioscler. Thromb. Vasc. Biol. 27 (2007) 1340–1345.
[103] F. Schorsch, E. Malle, W. Sattler, Selective uptake of high density lipoprotein-
associated cholesterylesters by differentiated Ob1771 adipocytes is modulated by
endogenous and exogenous lipoprotein lipase, FEBS Lett. 414 (1997) 507–513.
[104] E. Zsigmond, B. Fong, A. Angel, Dietary polyunsaturated fatty acids enhance the up-
take of high-density lipoprotein cholesterol ester by rat adipocytes, Am. J. Clin.
Nutr. 52 (1990) 289–299.
[105] N. Arakaki, T. Kita, H. Shibata, T. Higuti, Cell-surface H+-ATP synthase as a poten-
tial molecular target for anti-obesity drugs, FEBS Lett. 581 (2007) 3405–3409.
[106] A.D. Howard, P.B. Verghese, E.L. Arrese, J.L. Soulages, The beta-subunit of ATP
synthase is involved in cellular uptake and resecretion of apoA-I but does not
control apoA-I-induced lipid efﬂux in adipocytes, Mol. Cell. Biochem. 348 (2011)
155–164.
[107] J.R. Nofer, M. van Eck, HDL scavenger receptor class B type I and platelet function,
Curr. Opin. Lipidol. 22 (2011) 277–282.
[108] V.S. Dole, J. Matuskova, E. Vasile, A. Yesilaltay, W. Bergmeier, M. Bernimoulin, D.D.
Wagner, M. Krieger, Thrombocytopenia and platelet abnormalities in high-density
lipoprotein receptor-deﬁcient mice, Arterioscler. Thromb. Vasc. Biol. 28 (2008)
1111–1116.
[109] Y. Ma, M.Z. Ashraf, E.A. Podrez, Scavenger receptor BI modulates platelet reactivity
and thrombosis in dyslipidemia, Blood 116 (2010) 1932–1941.
[110] S.J. Korporaal, I. Meurs, A.D. Hauer, R.B. Hildebrand, M. Hoekstra, H.T. Cate, D.
Pratico, J.W. Akkerman, T.J. Van Berkel, J. Kuiper, M. Van Eck, Deletion of the
high-density lipoprotein receptor scavenger receptor BI in mice modulates throm-
bosis susceptibility and indirectly affects platelet function by elevation of plasma
free cholesterol, Arterioscler. Thromb. Vasc. Biol. 31 (2011) 34–42.
[111] M.F. Brodde, S.J. Korporaal, G. Herminghaus, M. Fobker, T.J. Van Berkel, U.J. Tietge,
H. Robenek, M. Van Eck, B.E. Kehrel, J.R. Nofer, Native high-density lipoproteins in-
hibit platelet activation via scavenger receptor BI: role of negatively charged phos-
pholipids, Atherosclerosis 215 (2011) 374–382.
[112] A.C. Calkin, B.G. Drew, A. Ono, S.J. Duffy, M.V. Gordon, S.M. Schoenwaelder, D.
Sviridov, M.E. Cooper, B.A. Kingwell, S.P. Jackson, Reconstituted high-density lipo-
protein attenuates platelet function in individuals with type 2 diabetes mellitus by
promoting cholesterol efﬂux, Circulation 120 (2009) 2095–2104.
[113] T.A. Pagler, A. Neuhofer, H. Laggner, W. Strobl, H. Stangl, Cholesterol efﬂux via HDL
resecretion occurs when cholesterol transport out of the lysosome is impaired,
J. Lipid Res. 48 (2007) 2141–2150.
[114] H. Stangl, G. Cao, K.L. Wyne, H.H. Hobbs, Scavenger receptor, class B, type
I-dependent stimulation of cholesterol esteriﬁcation by high density lipoproteins,
low density lipoproteins, and nonlipoprotein cholesterol, J. Biol. Chem. 273 (1998)
31002–31008.
[115] E.F. Stange, Compartmentalization of cholesterol in hepatic and intestinal cells: impli-
cations for bile and lipoprotein secretion, Biochem. Soc. Trans. 15 (1987) 189–192.
[116] K.C. Vickers, B.T. Palmisano, B.M. Shoucri, R.D. Shamburek, A.T. Remaley,
MicroRNAs are transported in plasma and delivered to recipient cells by
high-density lipoproteins, Nat. Cell Biol. 13 (2011) 423–433.
[117] W.S. Davidson, R.A. Silva, S. Chantepie, W.R. Lagor, M.J. Chapman, A. Kontush, Pro-
teomic analysis of deﬁned HDL subpopulations reveals particle-speciﬁc protein
clusters: relevance to antioxidative function, Arterioscler. Thromb. Vasc. Biol. 29
(2009) 870–876.
[118] T. Vaisar, S. Pennathur, P.S. Green, S.A. Gharib, A.N. Hoofnagle, M.C. Cheung, J. Byun,
S. Vuletic, S. Kassim, P. Singh, H. Chea, R.H. Knopp, J. Brunzell, R. Geary, A. Chait,
X.Q. Zhao, K. Elkon, S. Marcovina, P. Ridker, J.F. Oram, J.W. Heinecke, Shotgun pro-
teomics implicates protease inhibition and complement activation in the
antiinﬂammatory properties of HDL, J. Clin. Invest. 117 (2007) 746–756.
[119] A.M. Kambouris, P.D. Roach, G.D. Calvert, P.J. Nestel, Retroendocytosis of high den-
sity lipoproteins by the human hepatoma cell line, HepG2, Arteriosclerosis 10
(1990) 582–590.
[120] J.G. Strauss, R. Zimmermann, A. Hrzenjak, Y. Zhou, D. Kratky, S. Levak-Frank, G.M.
Kostner, R. Zechner, S. Frank, Endothelial cell-derived lipase mediates uptake and
binding of high-density lipoprotein (HDL) particles and the selective uptake of
HDL-associated cholesterol esters independent of its enzymic activity, Biochem. J.
368 (2002) 69–79.
[121] W.T. Chao, S.S. Fan, V.C. Yang, Visualization of the uptake of high-density lipopro-
tein by rat aortic endothelial cells and smooth muscle cells in vitro, Histochem. J.
34 (2002) 233–239.
[122] Z. Balazs, U. Panzenboeck, A. Hammer, A. Sovic, O. Quehenberger, E. Malle, W. Sattler,
Uptake and transport of high-density lipoprotein (HDL) and HDL-associated
alpha-tocopherol by an in vitro blood–brain barrier model, J. Neurochem. 89 (2004)
939–950.
